Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.34 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.33 |
| ▸ | MTAP | Q13126 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1038997 | 1.00 | GBA1 (0.36) | GBA1FUCA1S1PR5SPHK2SPHK1 | |
| SCHEMBL1038998 | 1.00 | GBA1 (0.36) | GBA1FUCA1S1PR5SPHK2SPHK1 | |
| SCHEMBL1039871 | 1.00 | GBA1 (0.36) | GBA1FUCA1S1PR5SPHK2SPHK1 | |
| SCHEMBL1037847 | 0.90 | GBA1 (0.39) | GBA1FUCA1S1PR5SPHK2SPHK1 | |
| SCHEMBL4583013 | 0.86 | SLC6A1 (0.32) | — | |
| SCHEMBL3874324 | 0.85 | RORC (0.35) | NPC1RAB9A | |
| SCHEMBL3874317 | 0.85 | RORC (0.35) | NPC1RAB9A | |
| SCHEMBL2683708 | 0.83 | SIGMAR1 (0.44) | GBA1FUCA1 | |
| SCHEMBL3907755 | 0.83 | SIGMAR1 (0.44) | GBA1FUCA1 | |
| SCHEMBL1941545 | 0.83 | SIGMAR1 (0.44) | GBA1FUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049514-B1 | NITRATE ESTERS OF PIPERIDINES | NOVARTIS AG (CH) | 2011-01-26 | — | — | EP | disclosed |
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| US-7625893-B2 | Substituted 4-phenyl piperidines for use as renin inhibitors | SPEEDEL EXPERIMENTA AG (CH) | 2009-12-01 | — | — | US | disclosed |
| US-20090088426-A1 | Substituted 4-Phenyl Piperidines for Use as Renin Inhibitors | SPEEDEL EXPERIMENTA AG | 2009-04-02 | — | — | US | disclosed |
| EP-1934207-B1 | SUBSTITUTED 4-PHENYL PIPERIDINES FOR USE AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| EP-1911758-A1 | Phenyl piperidine derivatives for use as renin inhibitors | Speedel Experimenta AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| EP-1908762-A2 | Organic compounds | Speedel Experimenta AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| EP-1908761-A1 | Organic compounds | Speedel Experimenta AG (CH) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088426-A1 | Substituted 4-Phenyl Piperidines for Use as Renin Inhibitors | REN, AGTR1, ACE | GBA1 544/4885FUCA1 1601/4885S1PR5 293/4885 |
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOS2, NOS1, NOS3 | GBA1 2863/4885FUCA1 3899/4885S1PR5 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.